Skip to content

Effect of Saptamrit Lauha and Darvyadi eye ointment in digital screen related eye diseases

Efficacy of Saptamrit Lauha and Darvyadi Raskriya in Computer and Visual Display Terminal Syndrome

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024934
Enrollment
60
Registered
2020-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H578- Other specified disorders of eye and adnexa

Interventions

Intervention1: Efficacy of saptamrit lauha and darvyadi raskriya in computer and visual display terminal syndrome: Composition of medicine 1 Saptamrit lauha Tablet Lauha bhasma, haritaki, vibhitaki,

Sponsors

Archana Gairola
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients between 18 to 40 years of age. 2 VDTs users complaining of symptoms like eye strain, blurred vision, headache, redness, burning sensation, irritated dry eyes, slow refocusing and muscle fatigue. 3 Patients having minimum three symptoms of CVDTS 4 Patients exposed to VDT screens for at least 1 year 5 Patients using VDTs for minimum 2 to 3 hrs/day continuously

Exclusion criteria

Exclusion criteria: 1 Patients of age below 18 years or above 40 years. 2 Patients not willing to register. 3 Known cases of any systemic or metabolic disorders. 4 Case of chronic or acute infections of eye. 5 Patients having any fundus/retinal pathology like Optic atrophy, Retinal disorder, Papilledema, etc.

Design outcomes

Primary

MeasureTime frame
Relief in symptoms like Eye strain, Blurred Vision,Headache, Redness, Burning sensation, Irritated dry eyes, Slow refocusing, Fatigue Timepoint: Symptoms will be assessed on day 1, 15 and 30 of the trial

Secondary

MeasureTime frame
Improvement in tear film stability investigated by Schirmers Test, Tear Film Breakup Time testTimepoint: Outcomes will be assessed on day 1, 15 and 30 of the trial

Countries

India

Contacts

Public ContactProf Dr Gunjan Sharma

Rishikul Campus UAU Haridwar

gunjan06purity@gmail.com8218428029

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026